Why did ETNB's EPS remain flat throughout 2024?

The EPS of ETNB remained flat throughout 2024 due to increased R&D expenses and general and administrative expenses, which offset the revenue from the company's core operations. The net loss of the company increased from $28.8 million in Q1 2023 to $51.7 million in Q1 2024, primarily due to heightened R&D and G&A costs. These increases reflect the company's intensified activities in clinical development and personnel expenses, which are critical for its pipeline progress. Despite the financial strain, the company has made significant strides in its clinical trials, particularly in the areas of liver and cardiometabolic diseases. The sustained EPS flatness indicates that the company's expenses are expanding at a similar rate to its revenue, thus maintaining a stable EPS.